Abnormal electrocardiogram and poor prognosis in heart failure with preserved ejection fraction

Tiantian He1, Chen Liu2, Weihao Liang2

  • 1Department of Obstetrics, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510620, PR China.

PubMed

Insights

Abnormal electrocardiograms (ECG) in heart failure with preserved ejection fraction (HFpEF) predict worse outcomes, including cardiovascular death and HF hospitalization. Physicians should carefully evaluate ECG findings in HFpEF patients for prognostic insights.

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Medical Diagnostics

Background:

  • Electrocardiogram (ECG) is routinely used in heart failure with preserved ejection fraction (HFpEF) management.
  • The prognostic implications of abnormal ECG findings in HFpEF are not fully established.
  • Previous studies on ECG prognostic markers in HFpEF often had limited sample sizes.

Purpose of the Study:

  • To investigate the prognostic value of baseline abnormal electrocardiograms (ECG) in patients with heart failure with preserved ejection fraction (HFpEF).
  • To utilize data from the large-scale TOPCAT trial to assess ECG's predictive power for adverse cardiovascular events in HFpEF.
  • To identify specific ECG abnormalities associated with poor prognosis in this patient population.

Main Methods:

  • Analysis of 1736 patients from the TOPCAT-Americas cohort with heart failure with preserved ejection fraction (HFpEF).
  • Patients were stratified into groups based on normal versus abnormal baseline electrocardiogram (ECG) findings.
  • Survival analyses were conducted for the primary composite endpoint (cardiovascular death, HF hospitalization, aborted cardiac arrest), all-cause death, cardiovascular death, and HF hospitalization.

Main Results:

  • Abnormal ECG was significantly linked to increased risk of the primary endpoint (HR: 1.480) and HF hospitalization (HR: 1.400) in HFpEF patients.
  • Bundle branch block predicted the primary endpoint and HF hospitalization, while atrial fibrillation/flutter was associated with all-cause and cardiovascular death.
  • Unspecified ECG abnormalities also correlated with a higher risk of the primary endpoint (HR: 1.213).

Conclusions:

  • Baseline abnormal electrocardiograms (ECG) are associated with a poorer prognosis in patients with heart failure with preserved ejection fraction (HFpEF).
  • Specific ECG findings like bundle branch block and atrial fibrillation have distinct prognostic implications.
  • Clinicians should consider abnormal ECG findings in HFpEF patients as significant indicators of adverse outcomes.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Electrocardiogram01:29

Electrocardiogram

An electrocardiogram (ECG or EKG) is a critical diagnostic tool that records the electrical signals produced by the heart during each heartbeat. This recording is achieved through electrodes placed strategically on the arms, legs, and chest. The electrocardiograph amplifies these signals and produces 12 distinct tracings, offering a comprehensive understanding of the heart's electrical activity.
Three major waveforms are present in a typical ECG recording: the P wave, the QRS complex, and...
2.5K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
20
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
1.0K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11